| | | | |

Enzyme May Help Doctors Determine Mesothelioma Prognosis

1220139_lab4Cancer researchers in New York say they have found a new way to help determine prognosis for people with malignant pleural mesothelioma. In a report in the Annals of Surgical Oncology, a team of doctors from Memorial Sloan Kettering Cancer Center say patients whose cancer cells tested positive for an enzyme called CD10 had more aggressive mesothelioma and shorter survival times.

Right now, stage (a measure of how far cancer has spread in the body) and type are the primary prognostic factors for mesothelioma. People with more advanced cancer or non-epithelioid mesothelioma tend to have poorer outcomes than people with epithelioid or early-stage mesothelioma. By offering another reliable prognostic factor, the new study suggests that CD10 can help make the process more effective, which may improve treatment planning.

CD10 is an enzyme coded by the MME gene and found in various normal tissues. It acts on certain hormones and cytokines in the body and has been linked to Alzheimer’s disease and acute lymphocytic leukemia as well as some lymphomas and myeloma. Although it is known to make certain cancers more aggressive, it has never been tested as a prognostic factor for mesothelioma.

The New York research team tested tumor cells from 176 mesothelioma cases for CD10 and found the enzyme in 93 percent of the sarcomatoid mesothelioma tumors and 79 percent of the biphasic tumors. Among the epithelioid mesothelioma tumors (the most common type), those whose cells all looked the same (non-pleomorphic) had lower CD10 expression, and better prognosis, than those with the pleomorphic subtype. No matter which kind of mesothelioma a patient had, those whose tumor cells tested positive for CD10 had the most aggressive cancer and the poorest outcomes.

“Overall survival for patients with positive CD10 expression was significantly shorter than that for patients with negative CD10 expression in all patients,” writes lead researcher Kyuichi Kadoka, MD, PhD, who is also associated with Kagawa University in Japan. The team concludes that CD10 can be used as an independent prognostic factor for mesothelioma patients.

Source:

Kadoka, K et al, “Tumoral CD10 Expression Correlates with Aggressive Histology and Prognosis in Patients with Malignant Pleural Mesothelioma”, January 22, 2015, Annals of Surgical Oncology, Epub ahead of print

Similar Posts

  • | |

    Mesothelioma survivor Paul Kraus, alive and well 19 years after writing “Surviving Mesothelioma and Other Cancers

    Paul Kraus is considered the longest documented mesothelioma survivor in the world. He was diagnosed in 1997 with mesothelioma so widespread that he was given little hope of survival. Not willing to give up, he worked with a team of doctors to create his own tailored treatment protocol. This protocol included dramatic life style change, experimental therapies, dietary changes, mind-body medicine, and other modalities. Paul was fortunate. The protocol he and his doctors created helped him keep the mesothelioma in check. His book “Surviving Mesothelioma and Other Cancers: A Patient’s Guide” details his cancer voyage, the decisions he made, and his philosophies about health and healing. This book is now the best-selling mesothelioma book in the world and has inspired…

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • |

    Mesothelioma Still Rising Despite Ban in Ireland

    A study in Ireland confirms that it can take many years for a ban on asbestos to have a measurable impact on a country’s rates of malignant mesothelioma. Mesothelioma is the most serious of a list of diseases – including lung cancer, pleural plaques, asbestosis, and others – linked with exposure to asbestos dust. Affecting the linings around the lungs and other organs, mesothelioma is often resistant to most cancer treatments and may be fatal within a year of diagnosis. According to the International Ban Asbestos Secretariat, Ireland is one of 55 countries that have enacted some type of asbestos ban. However, although Ireland banned asbestos in 2000, a new study published in Cancer Epidemiology shows that incidence of the…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Website Aims to Protect Homeowners from Mesothelioma

    Australia’s Cancer Council is trying to educate home renovators about their risk for mesothelioma with a new e-learning course. Australia has one of the highest per capita rates of mesothelioma in the world, largely because of several asbestos mining operations that were once located there. Although asbestos has been banned from building products in Australia since 1989, asbestos-linked diseases like mesothelioma, lung cancer, and asbestosis continue to pose a serious health concern. While mesothelioma has traditionally occurred among people exposed to asbestos on the job, Australia is now bracing for another “wave” of mesothelioma victims among homeowners who encounter asbestos while doing their own renovation projects. Cancer Council Australia has launched “kNOw asbestos in your home” in an effort to…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…